To be fair to Jpow and purely looking at numbers likely to come in for 2025 it's going to be a drastic drop from this year and last with 100m + profits. I think Daybue should continue to grow but not at a rate where they will hit 500m and trigger another milestone. Say they make 400m USD then royalties to Neuren will be 43m USD or about $65 m Aussie. The PRV has already been sold so that'll be it outside of interest. Not inconsiderable but still total revenue will be way down. And if they start a Ph3 costs will jump so the overall bottom line numbers could even be an overall loss. Not sure about 2026 just yet but should at least start Europe sales which will trigger a milestone and if COA is good at growing sales and Canada goes well then Daybue could hit 500 m USD and the numbers move strongly back up.
But that doesn't matter considering the stockpile of cash they've accumulated, they will get their shot with 2591. Jpow is wrong there. The Ph3 discussions will reach an agreement and Neuren will start the trial. They can easily fund it and so holding Neuren now is essentially a bet on either Ph3 success or a takeover. The Ph3 will run into 2026 the TO could be any time from tomorrow. That's my opinion at least.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)